Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with ... treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an ...

Novo Nordisk is doubling down on its collaboration ... focus to cover Novo’s defining indications—obesity and Type 2 diabetes—and increases the program cap to 20. If the programs hit their ...

Novo Nordisk provided significant funding to UK pharmacies for training, advertising and patient resources ... Compounding For Its Early-Generation Diabetes Drug Between 2021 and 2023, Novo ...

rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management. Novo Nordisk also noted 44 documented adverse ...